Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
This protein carries a polyhistidine tag at the N-terminus.
The protein has a calculated MW of 17.0 kDa. The protein migrates as 18-19 kDa,24-25 kDa and 28-30 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
>90% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Cynomolgus IL-17A, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.
The purity of Cynomolgus IL-17A, His Tag (Cat. No. ILA-C5249) is more than 90% and the molecular weight of this protein is around 41-56 kDa verified by SEC-MALS.
Immobilized Cynomolgus IL-17A, His Tag (Cat. No. ILA-C5249) at 2 μg/mL (100 μL/well) can bind Human IL-17 RA, Fc Tag (MALS verified) with a linear range of 0.2-3 ng/mL (QC tested).
Immobilized Cynomolgus IL-17A, His Tag (Cat. No. ILA-C5249) at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-Human IL17A Antibody, Human IgG1 with a linear range of 0.1-0.8 ng/mL (Routinely tested).
Immobilized Cynomolgus IL-17A, His Tag (Cat. No. ILA-C5249) at 2 μg/mL (100 μL/well) can bind Human IL-17 RC, Fc Tag (Cat. No. ILC-H5259) with a linear range of 10-80 ng/mL (Routinely tested).
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides comprehensive tools for neuroscience research, including neuroscience proteins, pre-formed fibrils (PFFs), neural antibodies, neural factors, and more—aiming to accelerate disease modeling, drug screening, and neural mechanism studies.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Vunakizumab | SHR-1314 | Approved | Jiangsu Hengrui Medicine Co Ltd | 安达静 | Mainland China | Plaque psoriasis | Suzhou Suncadia Biopharmaceuticals Co Ltd | 2024-08-20 | Non-radiographic axial spondyloarthritis; Autoimmune Diseases; Spondylitis, Ankylosing; Spondylarthritis; Graves Ophthalmopathy; Lupus Nephritis; Psoriasis; Graves Disease; Arthritis, Psoriatic; Plaque psoriasis | Details |
Ixekizumab | LY-2439821 | Approved | Eli Lilly And Company | 拓咨, Taltz | United States | Psoriasis | Eli Lilly And Company | 2016-03-22 | Diabetes Mellitus, Type 1; Non-radiographic axial spondyloarthritis; Pyoderma Gangrenosum; Depressive Disorder, Major; Spondylarthritis; Spondylitis, Ankylosing; Arthritis, Rheumatoid; Psoriasis; Lichen Planus; Arthritis, Psoriatic; Pemphigoid, Bullous; Pityriasis Rubra Pilaris; Plaque psoriasis | Details |
Xeligekimab | GR-1501 | Approved | Chongqing Zhixiang Jintai Biopharmaceutical Co Ltd, Genrix (Shanghai) Biopharmaceutical Co Ltd | 金立希 | Mainland China | Plaque psoriasis | Chongqing Zhixiang Jintai Biopharmaceutical Co Ltd | 2024-08-20 | Non-radiographic axial spondyloarthritis; Spondylarthritis; Lupus Nephritis; Psoriasis; Plaque psoriasis | Details |
Virulizin | Approved | Aptose | Virulizin, Virulizin-2 gamma | Mexico | Colorectal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Uterine Cervical Neoplasms; Sarcoma, Kaposi; Melanoma; Carcinoma, Renal Cell | null | 1997-01-01 | Stomach Neoplasms; Carcinoma, Renal Cell; Pancreatic Neoplasms; Colorectal Neoplasms; Uterine Cervical Neoplasms; Sarcoma, Kaposi; Melanoma | Details | |
Secukinumab | AIN-457; KB-03303A; NVP-AIN-457 | Approved | Novartis Pharma Ag | 可善挺, Scapho, Cosentyx | Japan | Psoriasis; Arthritis, Psoriatic | Novartis Pharma Ag | 2014-12-26 | Hidradenitis Suppurativa; Multiple Sclerosis; Ichthyosis, Lamellar; Tendinopathy; Psoriasis; Hyperkeratosis, Epidermolytic; Arthritis, Psoriatic; Tendon Injuries; Asthma; Lichen Planus; Graves Ophthalmopathy; Arthritis; Uveitis; Inflammation; Plaque psoriasis; Behcet Syndrome; Gastroenteritis; Dermatitis, Atopic; Crohn Disease; Ichthyosiform Erythroderma, Congenital; Spondylitis, Ankylosing; Necrobiosis Lipoidica; Multiple Sclerosis, Relapsing-Remitting; Diabetes Mellitus, Type 1; Giant Cell Arteritis; Pyoderma Gangrenosum; Lupus Erythematosus, Discoid; Alopecia Areata; Inflammatory Bowel Diseases; Metabolic Dysfunction-Associated Steatotic Liver Disease; Non-radiographic axial spondyloarthritis; Spondylarthritis; Arthritis, Rheumatoid; Rotator Cuff Injuries; Spondylarthropathies; Netherton Syndrome; Ichthyosis; Lupus Nephritis; Arthritis, Juvenile; Polymyalgia Rheumatica | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
QX002N | QX-002N | Phase 3 Clinical | Qyuns Therapeutics Co Ltd | Spondylitis, Ankylosing; Asthma | Details |
Roconkibart | JS005 | Phase 3 Clinical | Shanghai Junshi Biosciences Co Ltd | Non-radiographic axial spondyloarthritis; Spondylarthritis; Spondylitis, Ankylosing; Psoriasis; Plaque psoriasis | Details |
Izokibep | AFB-035; ABY-035; IMG-020; IMG020; ABY-035/AFO2 | Phase 3 Clinical | Affibody Ab | Spondylitis, Ankylosing; Psoriasis; Arthritis, Psoriatic; Hidradenitis Suppurativa; Uveitis; Plaque psoriasis | Details |
Sonelokimab | ALX-0761; MSB-0010841; M-1095 | Phase 3 Clinical | Ablynx Nv | Psoriasis; Arthritis, Psoriatic; Hidradenitis Suppurativa | Details |
Recombinant human IL-17A/F humanized antibody (Livzon Pharmaceutical Group) | LZM-012; LZM012; XKH004; XKH-004 | Phase 3 Clinical | Beijing Kanova Biomedical Technology Co Ltd, Livzon Pharmaceutical Group Inc | Spondylitis, Ankylosing; Psoriasis; Plaque psoriasis | Details |
Secukinumab Biosimilar(Celltrion) | CT-P55 | Phase 3 Clinical | Celltrion Inc | Multiple Sclerosis; Plaque psoriasis | Details |
Secukinumab Biosimilar(Mabtech) | CMAB-015; CMAB015 | Phase 3 Clinical | Taizhou Mabtech Pharmaceutical Co Ltd | Spondylitis, Ankylosing; Psoriasis; Plaque psoriasis | Details |
DMT-310 | DMT-310 | Phase 3 Clinical | Dermata | Acne Vulgaris; Rosacea | Details |
SIM-0335 | SIM-0335; SIM-335 | Phase 2 Clinical | BCY Pharm Co Ltd | Plaque psoriasis | Details |
SCT-650C | SCT650C; SCT-650-C; SCT-650C | Phase 2 Clinical | SinoCelltech Ltd | Non-radiographic axial spondyloarthritis; Autoimmune Diseases; Spondylitis, Ankylosing; Arthritis, Rheumatoid; Spondylarthritis; Plaque psoriasis | Details |
DC-853 | DC-853; LY4100511; LY-4100511 | Phase 2 Clinical | Dice Therapeutics Inc | Immune System Diseases; Plaque psoriasis | Details |
Isomyosamine | MYMD-1 | Phase 2 Clinical | Mymd Pharmaceuticals Inc | Anxiety; Frailty; Hashimoto Disease; Depression; Coronavirus Disease 2019 (COVID-19); Arthritis, Rheumatoid; Healthy Aging; Inflammation; Sarcopenia | Details |
ZL-1102 | ZL-1102; CB-001 | Phase 2 Clinical | Crescendo Biologics Ltd | Psoriasis; Plaque psoriasis | Details |
CJM-112 | CJM-112 | Phase 1 Clinical | Novartis Pharma Ag | Acne Vulgaris; Triple Negative Breast Neoplasms; Multiple Myeloma; Multiple Sclerosis; Psoriasis; Colorectal Neoplasms; Asthma; Hidradenitis Suppurativa; Acneiform Eruptions; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Plaque psoriasis | Details |
Tibulizumab | LY-3090106; LY3090106; ZB-106 | Phase 1 Clinical | Eli Lilly And Company | Sjogren's Syndrome; Arthritis, Rheumatoid; Sjogren-Larsson Syndrome | Details |
CNTO-6785 | CNTO-6785; FTC-001 | Phase 1 Clinical | Morphosys Ag, Johnson & Johnson Innovative Medicine | Arthritis, Rheumatoid; Spondylitis, Ankylosing; Psoriasis; Arthritis, Psoriatic; Pulmonary Disease, Chronic Obstructive | Details |
JNJ-61178104 | JNJ-61178104 | Phase 1 Clinical | Johnson & Johnson Innovative Medicine | Autoimmune Diseases | Details |
Secukinumab biosimilar (BioRay Pharmaceutical) | BR-201 | Phase 1 Clinical | BioRay Pharmaceutical Co Ltd | Autoimmune Diseases; Spondylitis, Ankylosing; Psoriasis; Plaque psoriasis | Details |
JNJ-63823539 | JNJ-63823539 | Phase 1 Clinical | Johnson & Johnson Innovative Medicine | Arthritis, Rheumatoid | Details |
Secukinumab biosimilar (CSPC Pharmaceutical Group) | SYS6012; SYS-6012 | Phase 1 Clinical | CSPC Pharmaceutical Group Ltd | Plaque psoriasis | Details |
Secukinumab biosimilar (Gan & Lee) | GLR1023; GLR-1023 | Phase 1 Clinical | Gan & Lee Pharmaceuticals | Plaque psoriasis | Details |
anti-IL-17A humanized monoclonal antibody(Fontacea ) | Phase 1 Clinical | Shandong Fangtansi Biopharmaceutical Co Ltd | Plaque psoriasis | Details | |
LEO-153339 | LEO-153339 | Phase 1 Clinical | Leo Pharma Inc | Details | |
HY-1770 | HY-1770; HT-17; HT17; YF02; HT25; GH02; HY1770 | Phase 1 Clinical | Suzhou Pharmavan Co Ltd | Plaque psoriasis; Dermatitis, Atopic | Details |
UCB-0159 | UCB-0159 | Phase 1 Clinical | Ucb Sa | Autoimmune Diseases | Details |
This web search service is supported by Google Inc.